BEIJING, Aug. 14, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited second quarter and half year financial results for the period ended June 30, 2014.
Second Quarter 2014 Financial Highlights (compared to the second quarter 2013)
Quarterly sales were $12.1 million, a decrease of 30.7% from $17.5 million in the prior year period. Sales for the first six months were $25.6 million, a decrease of 6.8% YoY from $27.5 million.
Gross profit was $9.1 million, a decrease of 33.3% from $13.6 million in the prior year period.
Gross margin was 75.0%, compared to 77.9% in the prior year period.
Net loss attributable to common stockholders was $2.2 million, or $(0.04) per basic and diluted share, compared to net income attributable to common stockholders of $1.3 million, or $0.02 per basic and diluted share, in the second quarter of 2013.
Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "While sales were impacted during the second quarter by short-term challenges from the external market environment, we are continuing to grow our sales channels and make strong progress in the development of our pipeline vaccines."
"In July, we received the first tranche of our RMB 60 million government grant to build a dedicated facility for the production of the EV71 vaccine, which is currently under review by the Center for Drug Evaluation. During the second quarter, we received our clinical trial license for the pneumococcal polysaccharide vaccine (PPV) from the CFDA and expect to begin trials later this year."
"Although we experienced decreased sales in the second quarter, we remain confident in our ability to execute our proven sales and marketing strategies, and continue to develop new vaccines that are both effective Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Related biology technology :1
. Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results2
. Sinovac to Participate in UBS Asia Healthcare CEO Summit in November 20133
. Sinovac Biotech Receives GMP Certification for Mumps Vaccine Production Facility4
. Sinovac to Present at 55th Annual BioPharma China Convention 2012 - Vaccine & Antibody Focus5
. Sinovac Announces Resignation of Chup Hung Mok from Board of Directors6
. Pressure BioSciences, Inc. Reports Second Quarter 2014 Financial Results and Provides Business Update7
. RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 20148
. Synthetic Biologics Reports Second Quarter 2014 Financial Results and Operational Highlights9
. MarketResearch.com: New Biotechnology Market Research Reports Added to Kalorama Information Knowledge Center10
. GenVec Reports Second Quarter 2014 Financial Results11
. BioSpecifics Technologies Corp. Reports Second Quarter 2014 Financial Results